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Summary 
It has recently been demonstrated that in vivo administration  of murine interleukin 12 (IL-12) 
to mice results in augmentation ofcytotoxic natural killer (NK)/lymphocyte-activated  killer cell 
activity, enhancement of cytolytic T  cell generation, and induction of interferon 7, secretion. 
In this study, the in vivo activity of murine IL-12 against a number of murine tumors has been 
evaluated. Experimental pulmonary metastases or subcutaneous growth of the B16F10 melanoma 
were markedly reduced in mice treated intraperitoneally  with IL-12, resulting in an increase in 
survival  time.  The therapeutic effectiveness of IL-12 was dose  dependent and treatment of 
subcutaneous tumors could be initiated up to 14 d after injection of tumor cells. Likewise,  established 
experimental hepatic metastases and established subcutaneous M5076 reticulum cell sarcoma and 
Renca renal ceU adenocarcinoma tumors were effectively treated by IL-12 at doses which resulted 
in no gross toxicity. Local peritumoral injection of IL-12 into established subcutaneous Renca 
tumors resulted in regression and complete disappearance of these tumors. IL-12 was as effective 
in NK ceLl-deficient  beige mice or in mice depleted of NK cell activity by treatment with antiasialo 
GM1, suggesting that NK cells are not the primary cell type mediating the antitumor effects 
of this cytokine. However, the efficacy of IL-12 was greatly reduced in nude mice suggesting 
the involvement of T cells. Furthermore, depletion of CD8 + but not CD4 + T cells significantly 
reduced the efficacy  of IL-12. These results demonstrate that IL-12 has potent in vivo antitumor 
and antimetastatic  effects against murine tumors and demonstrate as well the critical role of 
CD8 + T  cells in mediating the antitumor effects against subcutaneous  tumors. 
H 
uman IL-12 is a disulfide-bonded heterodimeric cytokine 
consisting  of a 40- and a 35-kD subunit (1, 2). The 
genes for this cytokine have been cloned (3, 4) and purified 
recombinant protein has been produced. A number of bio- 
logical properties of human IL-12 have  been evaluated  in vitro. 
Among its properties are the ability to act as a NK cell and 
T cell growth factor (5-7), to enhance NK/LAK cell cyto- 
lytic activity (1, 7-9), to augment cytolytic T cell responses 
(9), and to induce secretion of cytokines, particularly IFN-3,, 
from T and NK cells (1, 10). Since both T and NK cells have 
been implicated as antitumor effector cells (11) and IFN-3' 
has been shown to have antitumor activity in animals (12, 
13), IL-12 has the potential to be used as an immunomodula- 
tory cytokine in the therapy of malignancies. 
The ability to test the in vivo activities of IL-12 have  been 
limited since human IL-12 is inactive on murine cells, but 
recently the genes for murine IL-12 have been cloned (14). 
Injection of mice with recombinant murine IL-12 augments 
NK activity, enhances allogeneic cytolytic T cell responses, 
and induces secretion of IFN-% thus confirming the previ- 
ously described in vitro activities of IL-12 (Gately, M. K., 
R.  R.  Warrier,  S.  Honasoge,  D.  A.  Faherty,  S.  E.  Con- 
naughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, 
and M. Murphy, manuscript submitted for publication). Based 
on these in vivo results, the antitumor and antimetastatic ac- 
tivities of murine IL-12 against a number of murine malig- 
nancies have been evaluated. We demonstrate in this study 
that systemic administration of IL-12 can inhibit the growth 
of both established subcutaneous tumors and experimental 
pulmonary or hepatic metastases, and that local peritumoral 
injections of IL-12 can result in regression of  established sub- 
cutaneous  tumors.  Based on results  obtained  using mice 
deficient in lymphocyte subsets and antibody depletion ex- 
periments,  the antitumor efficacy of IL-12 is mediated pri- 
marily through CD8 + T  cells. 
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Mice.  C57BL/6, C57BL/6 bg/bg beige, C57BL/6 bg/+  het- 
erozygous beige control and BALB/c mice, 6-8 weeks of age, were 
purchased  from The Jackson  Laboratories,  (Bar  Harbor,  ME). 
BALB/c nude mice were obtained from Harlan-Spragne Dawley, 
Inc. (Madison, WI). Mice were routinely screened and found to 
be free of mycoplasma  and selected murine viruses. 
Tumor Celt Lines.  B16F10 malignant melanoma cells (15) and 
Renca renal cell adenocardnoma cells (16), obtained from Dr. R. 
W'dtrout (Biological Response Modifiers Program, Frederick, MD), 
were maintained in vitro in RPMI  1640 medium supplemented 
with 10% fetal bovine serum,  100 IU/ml penicillin,  100/zg/ml 
streptomycin,  25  mM N-2-hydroxyethylpiperazine-N'-2-ethane- 
sulfonic  acid,  25  mM  NaHCO3,  and  60  #g/ml  t-glutamine. 
M5076, a reticulum cell sarcoma (12, 17), was maintained as a sta- 
tionary suspension culture in RPMI 1640 supplemented with 17% 
equine serum (Hyclone Laboratories,  Inc., Logan, UT), 1 mM so- 
dium pyruvate, 50/zg/ml gentamicin, glutamine, penicillin, and 
streptomycin. All reagents for cell culture were purchased from 
GIBCO BILL (Gaithersburg, MD) unless  otherwise designated. 
All cell lines were found to be free of mycoplasma  and viruses as 
above. 
RecombinantMurine 11-,12.  Murine riD12 was expressed in CHO 
cells that had been stably transfected with the IL12 p40 and p35 
cDNAs and was purified as previously described (Gately, M. K., 
et al., manuscript submitted for publication). SDS-PAGE analysis 
of the purified IL-12 indicated it to be ~95% pure with a small 
amount of contaminating II,12 p40 monomer. Monomeric IL-12 
p40 does not bind to the II.-12 receptor (18) and lacks biological 
activity (3, 4).  Contamination by endotoxin, as assessed by the 
Limulus amebocyte assay, was  <5  EU/mg  Ib12.  The sp act of 
purified murine riD12, as determined by its ability to cause prolifer- 
ation of human PHA blasts  (18), was "~7  x  106 U/mg protein. 
For administration to mice, rlL-12 was diluted in PBS containing 
100/~g/ml mouse serum albumin (Miles Scientific, Naperville, IL 
or Sigma Chemical Co., St. Louis,  MO). 
Tumor Experiments.  Exponentially growing tumor cells were 
harvested by brief trypsinization (B16F10 and Renca), washed, and 
injected subcutaneously or intravenously into groups of 10 mice 
on day 0, and intraperitoneal treatment with various doses of I1.-12 
once per day five times per week was initiated between days I and 
28, depending on the experiment. Specific protocols are presented 
in the legends of individual experiments. The diameters of subcu- 
taneous tumors were measured twice weekly with calipers,  and 
volume was calculated by the formula: Vol  =  (longest diameter) 
x  (shortest diameter)  z (Gately,  M.  K.,  et al.,  manuscript  sub- 
mitted for publication). For metastasis experiments, approximately 
3 wk after intravenous injection of tumor cells, mice were killed 
and the number of metastases enumerated as previously described 
(15). Statistical evaluation of the data was performed using the non- 
parametric one-tailed Mann-Whitney U test (17). Experiments were 
repeated two to eight times, and data from representative experi- 
ments are presented. 
Antibody Depletion Experiments.  Antiasialo GM1 (anti-ASGM1) 
was  purchased from Biochemical Diagnostics,  Inc.  (Edgewood, 
NY). Mice were injected intraperitoneally with 0.4 ml of 1:5 dilu- 
tion of anti-ASGM1 or normal rabbit serum on the days indicated. 
Under these conditions of treatment with antiasialo GM1 splenic 
NK activity, is reduced to undetectable levels (17). 
Anti-CD4 (clone GK1.5, rat IgG2b) (19) and anti-CD8 (clone 
2.43, rat IgG2b) (20) hybridomas were purchased from the Amer- 
ican Type Culture Collection (l~.ockville, MD). Ascites were pre- 
pared in pristane-treated nude mice and Ig purified by the proce- 
dure of Reik et al. (21). Mice were injected intraperitoneally with 
1 mg oflg on the days indicated. Under these conditions, antibody 
treatment depleted >95% of the appropriate cell population in the 
spleen. 
Results 
We initially evaluated the effect of IL-12 on experimental 
pulmonary metastases of the B16F10 melanoma. After intra- 
venous injection with tumor cells on day 0, C57BL/6 mice 
were treated intraperitoneaUy beginning on day 1 with varying 
doses of IL-12 five times per week for 3 wk. At the end of 
the treatment period, there was a dose-dependent inhibition 
of experimental metastases in the IL-12-treated mice (Fig. 
1 A). In the group receiving 1 #g per injection, the median 
number of metastases was reduced to 41 compared with 200 
in the diluent-treated mice (p <0.005). To determine if treat- 
ment could be initiated at a time when metastases were al- 
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Figure  1.  Inhibition of B16F10 metastases by I1.-12. (A) Mice were in- 
jected intravenously with 2  x  10  s B16F10 cells on day 0 and treatment 
with diluent or varying doses of Ib12  per injection was initiated in- 
traperitoneaUy  on day 1. Mice  were treated five  times per week until animals 
were killed on day 22. (B) Treatment with 1/~g per injection of Ib12 
five times per week was initiated on day 7 and mice were killed on day 
22. Data are represented as mean _+ SE of 10 mice per group. 
1224  Antitumor Activity of IL-12 ready firmly established, mice were similarly  injected intra- 
venously  with tumor cells on day 0, but the initiation  of 
treatment was delayed  until day 7.  As shown in Fig.  1 B, 
under these experimental conditions,  treatment with  1/~g 
of IL-12 also significantly  reduced the number of experimental 
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metastases (p <0.0005). It is dear from these results that IL-12 
has potent antitumor activity in this experimental metastasis 
model and that treatment of animals with IL-12 can be initi- 
ated after metastases  have  already been established. 
A series of experiments was then performed to determine 
if IL-12  also  has  activity  against  subcutaneously  growing 
B16F10 tumors. Initially,  mice were injected subcutaneously 
with 106 tumor cells on day 0, and treatment with varying 
amounts of IL-12 was initiated on day 7 when small tumors 
were present in the animals. As preciously demonstrated with 
experimental metastases,  there was a dose-dependent inhibi- 
tion of tumor growth with maximal effects observed at a 
dose of 1 #g per injection (Fig.  2 A).  At all doses tested, 
no gross toxicity was evident  and all animals  survived the 
therapy,  although at the 5 #g dose some lethargy was ob- 
served.  To determine if IL-12 could increase  the survival  of 
B16F10  tumor-bearing  mice  and  to  test  if  the  effect  of 
prolonged IL-12 treatment on tumor growth, tumor-bearing 
mice were treated with 1/~g per injection of IL-12 five times 
per week until day 50. As seen in Fig. 2 B, there was a large 
increase in survival time of IL-12-treated mice compared with 
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Figure  2.  Inhibition of subcutaneous  growth of B16F10 tumors.  (A) 
Mice were injected  subcutaneously  with  106 B16F10 cells on day 0 and 
intraperitoneal  treatment  with  diluent  (O---O)  or 5/~g (H),  1 /~g 
(A---A), 0.1 /~g (A---A), or 0.01/~g (E]----~) of Ib12 was initiated on 
day 7. Mice were treated five times  per week until animals  were killed 
on day 22. (B) Survival of mice treated intraperitoneally with diluent (solid 
line) or 1/~g of IL-12 (dashed line) per injection five times per week through 
day 50. (C) Treatment of mice was initiated on day 14. Mice were treated 
intraperitoneally with diluent  (o---O)  or 1 #g of Ib12 (H)  per in- 
jection  five times  per week  for 3 wk. Data  are represented  as mean  _+ 
SE of 10 mice  per group. 
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Figure  3.  Inhibition ofM5076 experimental hepatic metastases and sub- 
cutaneous  tumor growth by II,-12. (A) Survival of mice injected intrave- 
nously on day 0 with 10  s M5076 tumor call and treated intraperitoneally 
with diluent (solid line) or 1/~g of IL-12 (dashed line) per injection five times 
per week for 3 wk was initiated on day 1.  (B) Mice were injected  sub- 
cutaneously  with  106 M5076  tumor  cells on  day 0 and intraperitoneal 
treatment  with diluent  (O---O)  or 1/~g of IL-12 (H)  per injection 
was initiated  on day 28.  Animals  were treated five times per week for 
4 wk. Data  represented  as mean  +  SE of 10 mice per group. diluent-treated control mice. Although tumor growth was 
suppressed for a prolonged time by IL-12 treatment, no "cures" 
were obtained, and tumors eventually grew, resulting in death 
of the animals. To evaluate the effect of IL-12 against larger 
B16F10 tumors, treatment with 1/zg of IL-12 per injection 
was delayed until day 14. As seen in Fig. 2 C, tumors grew 
progressively in control animals through day 29, at which 
point all animals had died. In contrast, the growth of tumors 
in mice treated with IL-12 was greatly diminished.  These 
results demonstrate that IL-12 has marked antitumor activity 
against subcutaneous B16F10 tumors. 
Since antitumor activity of IL-12 had only been demon- 
strated against the B16F10 melanoma, the antitumor efficacy 
of IL-12 was next evaluated against additional tumors. After 
intravenous injection of M5076 reticulum ceil sarcoma, ex- 
perimental hepatic metastases are formed (17). As seen  in Fig. 
3 A, diluent-treated mice have a median survival of 21 d with 
all animals dead by day 26, but treatment of mice with IL-12 
results in an increase in median survival time to 38 d. After 
subcutaneous injection ofM5076 tumor ceils, tumors develop 
much more slowly than in mice injected with B16F10 mda- 
noma cells. Thus, intraperitoneal treatment of  mice with IL-12 
was begun 4 wk after implantation of tumor ceils. Under 
these conditions, IL-12 markedly reduced tumor growth (Fig. 
3 B).  In these IL-12-treated animals,  spontaneous  hepatic 
metastases are also greatly reduced (Brenda, M. J., and T. D. 
Anderson, unpublished observation). Therefore, the antitumor 
activity of IL-12 is evident against both subcutaneous tumor 
growth and experimental hepatic metastases of the M5076 
reticulum cell sarcoma. 
To evaluate further the antitumor activity of IL-12, mice 
were injected subcutaneously with the Renca renal cell ade- 
nocarcinoma and treated with IL-12. The Renca renal cell 
adenocarcinoma is a murine tumor of spontaneous origin in 
BALB/c mice that mimics histologically renal cell carcinoma 
in humans (16) and is sensitive to various cytokines in vivo 
(16, 22). Beginning on day 14, intraperitoneal  treatment of 
mice with IL-12 resulted in a dramatic inhibition of tumor 
growth (Fig. 4 A), although complete regression of tumors 
was not observed. Since it has previously been reported that 
regression of the Renca tumor occurs after transfection of 
IL-4 into this tumor cell (22), mice bearing day 14 subcuta- 
neous Renca tumors were injected peritumorally with 1/~g 
of IL-12. As seen  in Fig. 4 B, tumors were markedly inhibited 
and, in fact, tumor regression occurred with no tumor de- 
tectable in 70% of treated mice after 60 d. Upon rechailenge 
with tLenca cells alone, tumor growth is greatly inhibited 
in these survivors (data not shown).  Thus, IL-12 has pro- 
nounced antitumor activity against the Renca renal cell ade- 
nocarcinoma and can, under certain conditions, result in regres- 
sion of established tumors. 
Since IL-12 has been demonstrated to have effects on both 
NK and T cells (1-10, 14, and Gately, M. K., et al., manuo 
script submitted for publication),  the antitumor activity of 
IL-12 might be mediated through either of these cell types. 
To determine if the antitumor efficacy  of IL-12 was primarily 
mediated through NK cells, its activity was evaluated against 
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Figure  4.  Inhibition of Renca tumors by IL-12. Mice were injected sub- 
cutaneously  on day 0 with 106 Renca tumor cells and  treatment with 
diluent (O---O) or 1/zg of IL-12 (H)  per injection five times per week 
for 4 wk was initiated on day 14. (A) Treatment by intraperitoneal  route. 
(/3) Treatment  by peritumoral route.  Data represented as mean  +  SE of 
10 mice per group. 
B16F10 tumors in NK ceil deficient bg/bg beige (23). Treat- 
ment of either bg/bg beige or phenotypicaily normal bg/+ 
heterozygotes with 1/zg per injection  of IL-12 resulted in 
a comparable degree of tumor inhibition (Fig. 5). To confirm 
and extend these results, Renca tumor-bearing BALB/c mice 
were depleted of NK cells using anti-ASGM1 and treated with 
IL-12. No loss of IL-12-induced antitumor efficacy  was ob- 
served in these NK cell-depleted mice (Fig. 6). Taken together, 
these results strongly suggest that the antitumor efficacy  of 
IL-12 is not mediated through NK ceils. 
To evaluate the potential role of T cells on IL-12-induced 
antitumor efficacy, the antitumor effect of IL-12 was tested 
against B16F10 tumors in nude mice (Fig. 7 A). Although 
there was a slight dday in tumor growth, the effect of IL-12 
was markedly diminished compared with that observed in 
euthymic mice. The greatly reduced activity of IL-12 was 
also obtained in BALB/c nude mice bearing syngeneic Renca 
tumors (Fig. 7 B). To evaluate further the requirement for 
T ceils in mediating IL-12-induced antitumor efficacy and 
to determine the role ofT cell subsets, Renca tumor-bearing 
mice were treated with anti-CD4 or anti-CD8 antibodies. 
As seen in Fig. 8, the activity of IL-12 is not affected in mice 
depleted of CD4 + T  ceils but substantially, although not 
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Figure  5.  Antitumor effects of IL-12 in NK ceU-deficient  beige mice. 
Animals were injected subcutaneously with 10~ B16F10 tumor cells on 
day 0 and intraperitoneal treatment with diluent (open symbols) or 1/~g  12000 
of Ib12 (filled symbols) per injection five times per week until the end of 
the experiment was initiated on day 14 in bg/+  hetemzygous mice (O/O)  E 
or bg/bg beige mice (A/A). Data are represented as mean  _+  SE of 10  "'  8000 
mice per group. 
completely, lost in mice treated with anti-CD8. These results 
demonstrate that CD8 + T ceils are critical  for mediating the 
antitumor effects  of IL-12. 
Discussion 
Using purified recombinant murine IL-12, we have demon- 
strated  that  this  cytokine  has  potent  antitumor  and  an- 
timetastatic activity against a number of murine tumors of 
various histological types.  Therapeutic intervention by sys- 
temic administration of IL-12 can be initiated when tumors 
or metastases are well established,  up to day 28 after  injec- 
A  0 
0---~0  [  ,/1  i\ 
o  ~,  A  ~/  /~  /,/,  o/ 
/  1 / 
/~"  t~,  / 
~O/_/O 
-  __-~/i-~L-~-,-,---~-"  ,"~=, 
1o  ,'5  2'0  is  3'0  ~s  40 
TIME (days) 
=, 
>o 
n~ 
0 
2 
4000 
T 
T 
z/T/TI/O 
.9o--"~/ ,.Lo/" 
I  I  I  I  I  I 
10  15  20  25  30  35 
TIME (days) 
Figure  7.  Reduced efficacy of II~12 in tumor-bearing nude mice. Mice 
were treated intraperitoneally five times per week for 4 wk with diluent 
(open symbols) or 1/~g Ib12 (closed symbols) beginning on day 7. Data are 
represented as mean _+ SE of 10 mice per group. (A) 136 (A/A) or BALB/c 
nude mice (O/O) were injected subcutaneously with 10~ B16F10 tumor 
cells on day O. (B) BALB/c (A/A) or BALB/c nude mice (O/O) were 
injected subcutaneously with 106 Renca tumor cells on day 0. 
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Figure  6.  Antitumor effects of ID12 in mice treated with anti-ASGM1. 
Animals were injected subcutaneously with 106 Renca tumor cells on day 
0 and intraperitoneal treatment with diluent (O---o) or Ib12 (O--O) 
was initiated on day 14 and continued five times per week for 4 wk. Other 
groups were treated with IL-12 beginning on day 14 and were injected 
intraperitoneally with either NRS (A---A) or anti-ASGM1 (Jk--A) on 
days 15, 17, 21, 24, 28, and 31. Data are represented as mean  _+  SE of 
10 mice per group. 
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Figure  8.  Effect of depletion of CD4 + or CD8 + T cells on antitumor 
efficacy of IL-12. Mice were injected subcutaneously with 106 Renca tumor 
cells on day 0 and intraperitoneal treatment five times per week until the 
end of the experiment with diluent (O--o) or 1/~g IIr  (~--4t) was 
initiated on day 14. Other groups of mice were injected with 1I:12 and 
either anti-CD4 (A---A) or anti-CD8 (A--A) on days 14, 21, and 28. 
Data are represented as mean  _+  SE of 10 mice per group. 
1227  Brunda et al. tion of tumor cells in the M5076 model, resulting in inhibi- 
tion of tumor growth, reduction in the number of metastases 
and an increase in  survival time.  Furthermore, after local 
peritumoral injections of IL-12,  established  subcutaneous 
tumors regress,  resulting in animals that are tumor free. 
The mechanism through which IL-12 exerts its antitumor 
activity is at present unknown, but based on its established 
in vivo activities several potential hypotheses can be suggested. 
IL-12 may have direct growth inhibitory effects on tumor 
cells. This is unlikely since addition of IL-12 in vitro to the 
murine tumor cells used in our studies resulted in no inhibi- 
tion of tumor cell proliferation (Brunch, M. J., and L. Luistro, 
unpublished observation) and there is reduced activity of this 
cytokine against tumors in nude mice (Fig. 7). However, IL-12 
has been shown to induce production and secretion of IFN-y 
(1, 10, and Gately, M. K., et al., manuscript submitted for 
publication), which might then in turn inhibit proliferation 
of tumor cells (24).  Such a proposed mechanism would be 
consistent with the lack of direct in vitro antiproliferative 
activity on tumor cells and the observed in vivo efficacy of 
IL-12. IFN-3' has been previously shown to have activity in 
vivo against murine tumors, although not to the extent ob- 
served with IL-12 (12, 13). Both T and NK cells can produce 
IFN-3, in response to IL-12 in vitro (1, 10), but if this hypoth- 
esis is correct, it would appear that T cell production of IFN-3/ 
is critical to the antitumor activity of IL-12 in vivo because 
the efficacy of IL- 12 is greatly reduced in athymic nude mice 
(Fig.  7).  It is unlikely that the antitumor efficacy of IL-12 
is directly an effect of the level of IFN-3' induced since IL-12 
induces an approximately fivefold higher level of IFN-y in 
nude mice than in euthymic mice (Hendrzak, J.,  and M. 
Brunch, unpublished observation) but IL-12 has a substan- 
tially reduced antitumor effect in nude mice (Fig.  7). IL-12 
retains some activity in nude mice, which may reflect the 
induction of IFN-3, or other cytokines. Treatment of mice 
with antibodies to IFN-'y may resolve some of these issues 
but in other studies (25, 26) this approach yielded conflicting 
results. Recently, IFN-3' knock out mice have been devel- 
oped (27) and the evaluation of the antitumor activity of IL-12 
in these animals could prove interesting. 
In addition to secretion of IFN-% stimulation of human 
NK or T cells with human IL-12 results in secretion of tumor 
necrosis factor (6), which can have antiproliferative effects 
on tumor cells (28). Recent data using cells from SCID mice 
demonstrate that incubation of these cells with murine IL-12 
resulted in no secretion of TNF in vitro using conditions 
that induced IFN-y (29).  Likewise, in preliminary experi- 
ments, no TNF was induced from normal murine spleen cells 
stimulated by murine IL-12 in vitro (Hendrzak, J., and M. 
Brunch, unpublished observations). Thus, it appears that IL-12 
is a relatively poor inducer of TNF in mice. However, the 
contribution of TNF or potentially other cytokines in medi- 
ating the antitumor effects of IL-12 in vivo needs to be ad- 
dressed in future experiments. 
IL-12  can both enhance the growth (5-7) and augment 
the cytolytic activity (1, 7-9, and Gately, M. K., manuscript 
submitted for publication) of NK/LAK and T cells. Thus, 
the antitumor efficacy of IL-12 might be mediated through 
stimulation of one or both these lymphocyte populations. 
It is unlikely that NK cells are primarily involved since the 
antitumor  activity  of IL-12  is  maintained  in  both  NK 
cell-deficient beige mice (Fig. 5) and in mice depleted of NK 
cells with anti-ASGM1 (Fig. 6). However, T cells appear to 
be necessary to obtain maximal effects since the efficacy of 
IL-12 treatment is greatly diminished in nude mice (Fig. 7). 
Under other experimental conditions, the antitumor activity 
of a number of cytokines has been reported to be dependent 
upon T  cells (22, 30, 31). It has been suggested that IL-12 
promotes the development of Thl cells (32, 33), and these 
in turn may positively regulate the expansion and/or activa- 
tion of other lymphoid cell populations. After depletion of 
T cell subsets with mAbs, the efficacy of IL-12 was decreased 
in mice depleted of CD8 + T  cells but remained intact in 
mice depleted of CD4 + T cells (Fig.  8). These results indi- 
cate that CD8 + T  cells are the critical cell type for medi- 
ating the antitumor efficacy of IL-12.  The efficacy of IL-12 
is not completely eliminated in CD8 + T cell-depleted mice. 
This finding may reflect the effect of IL-12  on the few re- 
maining CD8 + T cells or on other cell types, such as mac- 
rophages. It appears that CD4 + T cells are not necessary for 
mediating the antitumor effects of IL-12, which is puzzling 
in light of the effects of IL-12 on CD4 + Thl cells (32, 33). 
However, since IL-12 also stimulates cytokine secretion from 
NK cells (1, 10), the cytokine-secreting function of CD4 + 
T  cells may be replaced by NK cells under the conditions 
used in these tumor therapy experiments. In addition,  ex- 
ogenously administered IL-12 may at least partially replace 
any requirement for endogenously produced IL-2, since the 
biological activities of IL-12 substantially overlap those of IL-2. 
A number of cytokines, including IFN-ol and IL-2, have 
been demonstrated to be active in murine tumor models (11-13, 
15, 30) and, subsequently, to be useful in the treatment of 
human malignancies (11, 34,  35).  In contrast, with other 
cytokines, such as IFN-y or TNF, the activity demonstrated 
in animal models (11-13, 31) has not translated to successful 
use of these proteins for therapy of human malignancies (11, 
34). The data presented in this study clearly establish IL-12 
as a cytokine that has potent antitumor and antimetastatic 
activities in several murine tumor models through an immune- 
mediated, T cell-dependent mechanism. Future clinical trials 
with this cytokine will determine if the activity demonstrated 
in animals can be translated into efficacy against human malig- 
nancies. 
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